DexCom (DXCM) Projected to Post Earnings on Wednesday

DexCom (NASDAQ:DXCM) is expected to release its Q2 2025 earnings data after the market closes on Wednesday, July 30th. Analysts expect DexCom to post earnings of $0.45 per share and revenue of $1.13 billion for the quarter. DexCom has set its FY 2025 guidance at EPS.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the firm posted $0.32 EPS. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Trading Up 1.3%

NASDAQ:DXCM opened at $85.12 on Wednesday. DexCom has a one year low of $57.52 and a one year high of $113.28. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a market cap of $33.38 billion, a P/E ratio of 63.52, a P/E/G ratio of 1.79 and a beta of 1.44. The firm has a 50-day simple moving average of $84.49 and a 200-day simple moving average of $80.20.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nicholas Augustinos sold 3,672 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company’s stock, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock valued at $2,281,732 over the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC grew its stake in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the period. Focus Partners Wealth grew its stake in shares of DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares during the period. Empowered Funds LLC grew its stake in shares of DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares during the period. Finally, Brighton Jones LLC grew its stake in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. Mizuho boosted their price objective on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Wall Street Zen upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Friday, July 18th. Truist Financial assumed coverage on shares of DexCom in a research report on Monday, June 16th. They set a “buy” rating and a $102.00 target price on the stock. Canaccord Genuity Group boosted their target price on shares of DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Finally, Citigroup reissued a “buy” rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.60.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.